Every year, malaria kills around 600,000 people. Most of them are children under five. Most of them are in sub-Saharan Africa. And despite decades of research, the parasite responsible — *Plasmodium falciparum* — has shown a persistent talent for developing resistance to the drugs we throw at it.
Now, an international team of researchers believes they've found its Achilles heel.
Scientists from the University of Nottingham, the National Institute of Immunology in New Delhi, the University of Groningen, the Francis Crick Institute, and three other leading research institutions have identified a protein called Aurora-related kinase 1 — ARK1 — that acts as the parasite's essential 'traffic controller' during cell division.
The study, published in March 2026, explains what ARK1 does and why its discovery matters so much.
When *Plasmodium* divides inside red blood cells, it uses a molecular structure called the spindle to separate and distribute its genetic material into new parasite cells. ARK1 controls the spindle — it organises this process, ensuring the division happens correctly and new parasites form successfully. Without ARK1, the spindle cannot function properly. The parasite cannot replicate. It cannot complete its life cycle. And critically: it cannot be transmitted from human hosts to mosquitoes, breaking the chain of infection.
When the researchers experimentally disabled ARK1, the malaria parasite simply stopped. No replication. No transmission. No disease.
But what makes this discovery particularly valuable — and why it represents a genuine blueprint for drug development rather than just an interesting biological finding — is where ARK1 sits in the evolutionary tree.
The malaria parasite's version of ARK1 is structurally and functionally different from the equivalent kinase proteins found in human cells. That divergence is enormously significant. It means it should be possible to design drugs that precisely target the parasite's ARK1 without touching human proteins — avoiding the toxicity and side effects that have complicated the development of other antiparasitic treatments.
'This discovery provides a blueprint for future drug development targeting the malaria transmission cycle,' the researchers explained.
Malaria drug resistance is one of the most pressing challenges in global health. The current frontline treatment — artemisinin-based combination therapies — is beginning to show resistance in parts of Southeast Asia and East Africa. New mechanisms of action are urgently needed: drugs that hit entirely different targets, giving the parasite no pre-existing resistance pathway to exploit.
ARK1 is exactly that kind of target. It's essential to the parasite. It's absent from healthy human cells in the same form. And now we know how to find it.
Sixty million children will be born in sub-Saharan Africa this year. Roughly forty million of them will be exposed to malaria before they turn five.
This is one more step on the long road to a world where that number is zero. 🌍